The alliance announced Tuesday will span multiple programs in infectious diseases and cancer. Specific indications in those therapeutic areas were not disclosed, but Orna could earn up to $3.5 billion ...

Veteran immunologist and former Pfizer R&D leader joins Circurna to advance its circular RNA therapeutic platform ...

“Circular RNA technology is poised to transform vaccine development as well the treatment of cancers, autoimmune and other diseases. Circurna reflects who we are today and the future we are working ...

During the COVID-19 pandemic, mRNA-based vaccines led the charge against the SARS-CoV-2 virus. These therapies would not have existed were it not for the painstaking mRNA research that began years ...

The recognition of mRNA molecules as a transformative class of therapeutic drugs has soared, particularly with the development of COVID 19 mRNA vaccines. The cancer treatment landscape is similarly ...

A new set of strategies is being investigated to combat the coronavirus disease 2019 (COVID-19), as well as other future viral pandemics. This includes the use of novel antigens, adjuvants, and ...

Bristol Myers Squibb (NYSE:BMY) has agreed to acquire privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash. Orbital Therapeutics is advancing a new generation of RNA ...

The ELAV protein binds to specific regions of the precursor RNA, namely to so-called reverse complementary sequences (RCMs) in the introns flanking the "backsplice junction" (BSJ) that is crucial for ...

The first RNA-based medicinal products to attract widespread attention were, of course, the RNA-based vaccines against SARS-CoV-2. But now other RNA-based medicinal products are emerging. RNA-based ...